Loading...
Oral anticoagulation therapy is the standard for preventing stroke in patients with atrial fibrillation (AF). Aspirin, the alternative for warfarin-ineligible AF patients, is less effective than warfarin for stroke prevention (JAMA 2002; 288:2441). In a new, industry-sponsored trial, researchers randomized 6706 AF patients (mean age, 70; 66% men) with at least one stroke risk factor to receive dual antiplatelet therapy — clopidogrel (75 mg/day) plus aspirin (75–100 mg/day) — or oral anticoagulation therapy, usually warfarin (target INR, 2–3). Baseline use of other medications (ACE inhibitors in 54%, ARBs in 15%, beta-blockers in 57%, digoxin in 37%, and statins in 38%) was similar in the two groups. The primary endpoint was the first incide…